The global infectious disease immunoassay market is expected to reach USD 2,233.0 million by 2023 from USD 1,642.5 million in 2018, growing at a CAGR of 6.3%. Increasing incidence of chronic and infectious diseases; technological advancements in immunoassay instruments and the introduction of novel automated systems; growth in biotechnology and biopharmaceutical industries; increasing adoption of immunoassay-based point-of-care testing and rapid testing are some of the major factors driving the growth of the global infectious disease immunoassay market. These driving factors consequence to the rapid adoption of these new devices, thus propelling the market growth.
North America dominates the infectious disease immunoassay market with the North America accounted major market share in 2017. Established healthcare infrastructure; and technological advancements in immunoassay instrumentation are some of the major driving factors driving the growth of this market in North America. The Asian infectious disease immunoassay market is poised to grow at the highest CAGR during the forecast period owing to improving healthcare infrastructure and rising awareness about advanced point-of-care diagnostics among people in the region. The rising focus of prominent players on the Asian infectious disease immunoassay market is another factor driving its growth. Furthermore, emerging countries such as India and China provides immense growth opportunities to the infectious disease immunoassay manufacturers.
Prominent players in the infectious disease immunoassay market are Abbott Laboratories, Inc., Siemens AG, Beckman Coulter, Inc., Sysmex Corporation, Biomerieux Sa, Ortho Clinical Diagnostics, Inc., DiaSorin, QIAGEN N.V, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Agilent Technologies.
This research report covers the global suture anchor device market by method; product & services; platform; specimen type; disease type; end user; and geography.
Table of Contents
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered in the Study
2 Research Methodology
2.1 Market Size Estimation
2.2 Market Crackdown and Data Triangulation
2.3 Market Share Estimation
2.3.1 Key Data Points Taken From Secondary Sources
2.3.2 Key Data Points Taken From Primary Sources
3 Executive Summary
4 Premium Insights
5 Market Overview
5.2 Market Dynamics
6 Infectious Diesease Immunoassay Market, By Products and Services
6.2 Reagents & Kits
6.2.2 Rapid Tests
6.2.4 Western Blot
6.2.5 Other Reagents and Kits
6.3.1 Open-Ended Systems
6.3.2 Close-Ended Systems
6.4 Software & Services
7 Infectious Diesease Immunoassay Market, By Platform
7.2 Chemiluminescence Immunoassay (CLIA)
7.3 Fluorescence Immunoassay (FIA)
7.4 Colorimetric Immunoassay (CI)
7.5 Radioimmunoassay (RIA)
7.6 Other Platforms
8 Infectious Diesease Immunoassay Market, By Specimen Type
9.6 Other Specimens
9 Infectious Diesease Immunoassay Market, By Disease Type
10 Infectious Diesease Immunoassay Market, By End User
10.2 Hospitals and Clinical Laboratories
10.3 Pharmaceutical & Biotechnology Companies and Cros
10.4 Research and Academic Laboratories
10.5 Other End Users
11 Infectious Diesease Immunoassay Market, By Region
11.2 North America
11.3.6 Rest of Europe (RoE)
11.4 Asia Pacific
11.4.4 Rest of Asia Pacific
11.5 Latin America
11.6 Middle East and Africa
12 Competitive Landscape
12.2 Market Share Analysis
12.3 Competitive Situation and Trends
13 Company Profiles*
13.2 Abbott Laboratories, Inc.
13.3 Siemens AG
13.4 Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
13.5 Sysmex Corporation
13.6 Biomérieux Sa
13.7 Ortho Clilnical Diagnostics, Inc.
13.9 Qiagen N.V.
13.10 Thermo Fisher Scientific, Inc.
13.11 Becton, Dickinson and Company
13.12 Bio-Rad Laboratories, Inc.
13.13 Agilent Technologies
Benchmarking the rapid strategy shifts of the Top 100 companies in the Infectious Disease Immunoassay MarketRequest For Special Pricing